



United Business Media

For immediate release

25 November 2004

UBM Moves Further Online in French Healthcare

In a joint venture with German software company CompuGROUP Holding AG, United Business Media has acquired Axilog – France’s leading practice management software provider – from France Telecom.

UBM has a 25% stake in the joint venture which acquired Axilog.

This deal reinforces the strategy of UBM’s healthcare subsidiary CMPMedica to gain deeper access to doctors’ desktops in France, resulting in further opportunities at the point of prescription. Axilog has an approximate 25% of the practice management software market. This enhances the position of CMPMedica’s market leading French brand, Vidal and provides an opportunity to take advantage of the French government’s initiatives to increase the sharing of electronic patient records.

-Ends-

For further information, please contact:

Michael Waring
Colin Browne

United Business Media
The Maitland Consultancy

020 7921 5031
020 7379 5151

Notes:

CMPMedica, a leading provider of healthcare information, communication and services, is an international company with a reputation for the quality and innovation of its products.

United Business Media acquired CMPMedica on 30th July 2004 – details are on the UBM website at www.unitedbusinessmedia.com

Axilog was created in 1988 and a subsidiary of France Telecom since January 2001, Axilog is the largest practice management software supplier in France with around 20,000 users under contract making up around 25% of French doctors in practice.

The company is based in Montpellier in the South of France and employs around 120 staff, based both in its head office and in local centres throughout France.

VIDAL Drug Directory

- Launched in 1911, VIDAL has high brand recognition in France, not only with the medical profession and the pharmaceutical industry, but also with the general public. It is the “gold standard” for drug information. VIDAL’s red book is published annually (in January) with two updates during the year (in May and October). On each of the products listed in the drug directory, VIDAL provides full disclosure information in the form of drug monographs summarising official information on key characteristics for each drug, specifically composition, indications, dosage, posology, contraindications, interactions, side effects, price and pharmacology.

For information on **CompuGroup** go to:

www.compugroup.com/english/cg_profile.htm

This press release includes statements which are not historical facts and are considered “forward-looking” within the meaning of Section 27 of the Securities Act of 1933, as amended. These forward-looking statements reflect UBM’s current views about future events, business and growth strategy and financial performance. These forward-looking statements are identified by their use of terms and phrases such as “believe,” “expect,” “plan,” “anticipate,” “on target” and similar expressions identifying forward-looking statements. Investors should not rely on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from UBM’s expectations. UBM expressly does not undertake any duty to update forward-looking statements. Management does not attempt to update forecasts unless conditions materially change.